Compare · MMED vs WST
MMED vs WST
Side-by-side comparison of MiniMed Group Inc. (MMED) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMED and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.52B, about 4.6x MMED ($5.32B).
- MMED has been more active in the news (8 items in the past 4 weeks vs 1 for WST).
- WST has more recent analyst coverage (18 ratings vs 13 for MMED).
- Company
- MiniMed Group Inc.
- West Pharmaceutical Services Inc.
- Price
- $18.91-4.97%
- $348.50-1.36%
- Market cap
- $5.32B
- $24.52B
- 1M return
- +6.99%
- -
- 1Y return
- +3.56%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 8
- 1
- Recent ratings
- 13
- 18
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest MMED
- MiniMed to Participate in Upcoming Investor Conferences
- SEC Form DEFA14A filed by MiniMed Group Inc.
- SEC Form DEF 14A filed by MiniMed Group Inc.
- MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor
- MiniMed Group Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SVP, Gen. Counsel, Corp. Sec. Wills Courtney Nelson covered exercise/tax liability with 1,762 shares, decreasing direct ownership by 1% to 136,384 units (SEC Form 4) (withholding tax)
- EVP Ch. Prod. & Tech Officer Dianaty Ali covered exercise/tax liability with 8,012 shares, decreasing direct ownership by 2% to 315,158 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Dallara Que covered exercise/tax liability with 31,350 shares, decreasing direct ownership by 3% to 884,749 units (SEC Form 4) (for tax liability)
- EVP, Chief Financial Officer Spooner Chad covered exercise/tax liability with 23,301 shares, decreasing direct ownership by 6% to 362,707 units (SEC Form 4) (withholding obligation)
- SVP, Chief HR Officer Chandrasena Gillian covered exercise/tax liability with 2,099 shares, decreasing direct ownership by 1% to 172,745 units (SEC Form 4) to cover withholding tax
Latest WST
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target